Astaxanthin Comes From a Tank. Fucoidan Still Comes From the Sea.

Marine skincare is having a moment, and the pitch almost always leans on the same word: biotechnology. Marine actives are framed as the sustainable alternative to older extraction methods, grown in tanks and bioreactors rather than pulled from open water. That framing holds for one of the category's most common ingredients and breaks down for another, and the gap says more about how this ingredient class actually reaches a jar than most trend copy admits.

A tank-grown antioxidant

Astaxanthin is the clean case. The reddish carotenoid, prized for antioxidant claims in anti-aging formulas, comes from Haematococcus pluvialis, a freshwater microalga that turns red under stress and concentrates the pigment as it does. Commercial production is genuinely industrial: Cyanotech grows it in Hawaii, Algatechnologies cultivates it in Israel, Fuji Chemical Industry produces it in Japan, and Beijing Ginko Group supplies it from China. AstaReal, a Swedish-founded producer with US operations, grows its algae in closed indoor photobioreactors fed with filtered air, filtered water and controlled lighting rather than open ponds. None of these companies harvest wild algae populations. The entire supply chain for cosmetic-grade astaxanthin runs through cultivation, not extraction from the wild.

A wild-harvested pest

Fucoidan does not follow the same pattern. The sulfated polysaccharide, marketed for hydration and soothing claims, is extracted mainly from two brown seaweeds: wakame (Undaria pinnatifida) and bladderwrack (Fucus vesiculosus). The dominant global supplier is Marinova, a Tasmania-based company that describes itself as the world's only supplier of high-purity, certified organic fucoidan with what it calls global regulatory acceptance. Marinova's own sourcing page states that its extracts come from wild, certified-organic seaweed, with wakame harvested from Australian waters and bladderwrack from Nova Scotia, alongside other stocks from Brittany and Patagonia. The company describes harvesting rules on cutting height, monitoring and reporting meant to leave canopy for other intertidal species, plus batch-level quality audits. Nothing on that page describes cultivation.

There is a sharper detail underneath the sourcing map. Undaria pinnatifida is not a native Tasmanian species. It was first recorded in eastern Tasmania in 1988, likely introduced through ballast water from ships, and it now sits on Australia's Priority Marine Pest List. It is also one of only two seaweeds included on the Invasive Species Specialist Group's list of the 100 worst invasive alien species worldwide, the other being Caulerpa taxifolia. Tasmanian researchers have run active removal programs against it in marine reserves. None of this makes Marinova's harvest illegitimate. It arguably means the harvest doubles as pest control. But it complicates the "pure, wild, sustainable" framing that dominates fucoidan marketing, since the wild stock in question is, by Australia's own classification, a problem the state is otherwise trying to manage down.

Cultivation exists. It just serves a different buyer.

None of this is because seaweed cultivation is immature. Wakame is one of the most heavily farmed marine crops on earth. China produced roughly 225,600 tonnes of dried Undaria in 2020, equivalent to something like 2.2 million tonnes fresh weight, according to industry production estimates. South Korea grows around 800,000 tonnes of seaweed across three species annually, with wakame accounting for roughly half of that volume. Japan, the largest consumption market, imports most of its supply from Chinese and Korean farms rather than growing it domestically. Cultivation infrastructure for this exact species exists at enormous scale. It simply serves the food industry, not the cosmetic-ingredient supply chain, where the leading fucoidan producer has chosen wild stock instead, in a region where the same species is officially classified as a pest rather than a crop.

The likely reason is consistency rather than romance. Seaweed farmed intensively for food is bred and harvested on cycles optimized for yield and texture, not for a specific bioactive polysaccharide fraction, and fucoidan content in brown algae varies by species, season and growing conditions. A supplier selling a high-purity extract with defined specifications has an incentive to work from known, tested wild populations rather than switch to farmed biomass whose fucoidan profile has not been validated the same way. Marinova markets this as a strength, not a compromise: its own materials describe the sourcing as "wild and sustainable," treating wild origin as a selling point rather than something cultivation would improve on.

The practical takeaway for anyone evaluating a marine-ingredient claim is that "blue biotechnology" is not a category-wide description. It accurately describes how astaxanthin reaches the market. It does not describe how fucoidan does, even though both get bundled into the same sustainability pitch in trend coverage, and in fucoidan's case the wild-origin story has a regulatory footnote that the marketing leaves out. A brand or formulator citing marine-active sourcing as evidence of a lower-impact supply chain should specify which ingredient, whose harvest, and whether the source species carries a regulatory status in its country of origin worth disclosing.

Sources: Marinova · Tasmania Department of Natural Resources and Environment